OCUL

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 22.70 USD with a low forecast of 18.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ocular Therapeutix Inc revenue for the last quarter amounts to 14.54M USD, decreased -5.71 % YoY.

Ocular Therapeutix Inc. EPS for the last quarter amounts to -0.38 USD, increased 72.73 % YoY.

Ocular Therapeutix Inc (OCUL) has 274 emplpoyees as of December 15 2025.

Today OCUL has the market capitalization of 3.10B USD.